

Kepa B Uribe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4551142/publications.pdf>

Version: 2024-02-01

43
papers

1,722
citations

516710

16
h-index

345221

36
g-index

44
all docs

44
docs citations

44
times ranked

1506
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 2020, 21, 6275.	4.1	993
2	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. International Journal of Molecular Sciences, 2018, 19, 3426.	4.1	78
3	Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. International Journal of Molecular Sciences, 2020, 21, 4725.	4.1	66
4	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2248-2260.	2.4	60
5	Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. Journal of Biological Chemistry, 2018, 293, 7408-7422.	3.4	57
6	Functional characterization of splicing and ligand-binding domain variants in the LDL receptor. Human Mutation, 2012, 33, 232-243.	2.5	37
7	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. Scientific Reports, 2017, 7, 15282.	3.3	37
8	Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants. International Journal of Molecular Sciences, 2018, 19, 1676.	4.1	37
9	Membrane Permeabilization by Pore-Forming RTX Toxins: What Kind of Lesions Do These Toxins Form?. Toxins, 2019, 11, 354.	3.4	28
10	Molecular mechanisms of lipotoxicity-induced pancreatic β -cell dysfunction. International Review of Cell and Molecular Biology, 2021, 359, 357-402.	3.2	28
11	Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Scientific Reports, 2020, 10, 1727.	3.3	23
12	<i>In Vivo</i> Evaluation of Multifunctional Gold Nanorods for Boron Neutron Capture and Photothermal Therapies. ACS Applied Materials & Interfaces, 2021, 13, 49589-49601.	8.0	23
13	Phospholipase A activity of adenylate cyclase toxin mediates translocation of its adenylate cyclase domain. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6784-E6793.	7.1	22
14	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis, 2019, 289, 162-172.	0.8	21
15	Calpain-Mediated Processing of Adenylate Cyclase Toxin Generates a Cytosolic Soluble Catalytically Active N-Terminal Domain. PLoS ONE, 2013, 8, e67648.	2.5	19
16	Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. Journal of Materials Chemistry B, 2021, 9, 410-420.	5.8	17
17	Adenylate Cyclase Toxin Promotes Internalisation of Integrins and Raft Components and Decreases Macrophage Adhesion Capacity. PLoS ONE, 2011, 6, e17383.	2.5	15
18	miR-27b Modulates Insulin Signaling in Hepatocytes by Regulating Insulin Receptor Expression. International Journal of Molecular Sciences, 2020, 21, 8675.	4.1	14

#	ARTICLE	IF	CITATIONS
19	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. <i>Atherosclerosis</i> , 2017, 263, 163-170.	0.8	13
20	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model. <i>Small</i> , 2022, 18, e2105915.	10.0	13
21	Adenylate Cyclase Toxin promotes bacterial internalisation into non phagocytic cells. <i>Scientific Reports</i> , 2015, 5, 13774.	3.3	12
22	Membrane Permeabilization by Bordetella Adenylate Cyclase Toxin Involves Pores of Tunable Size. <i>Biomolecules</i> , 2019, 9, 183.	4.0	12
23	Understanding the Mechanism of Translocation of Adenylate Cyclase Toxin across Biological Membranes. <i>Toxins</i> , 2017, 9, 295.	3.4	11
24	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. <i>Biomedicines</i> , 2020, 8, 373.	3.2	11
25	Engineered Repeat Protein Hybrids: The New Horizon for Biologic Medicines and Diagnostic Tools. <i>Accounts of Chemical Research</i> , 2021, 54, 4166-4177.	15.6	11
26	MLb-LDLr. <i>JACC Basic To Translational Science</i> , 2021, 6, 815-827.	4.1	10
27	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13602.	4.1	10
28	Ca ²⁺ Influx and Tyrosine Kinases Trigger Bordetella Adenylate Cyclase Toxin (ACT) Endocytosis. Cell Physiology and Expression of the CD11b/CD18 Integrin Major Determinants of the Entry Route. <i>PLoS ONE</i> , 2013, 8, e74248.	2.5	9
29	Cholesterol stimulates the lytic activity of Adenylate Cyclase Toxin on lipid membranes by promoting toxin oligomerization and formation of pores with a greater effective size. <i>FEBS Journal</i> , 2021, 288, 6795-6814.	4.7	6
30	p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro. <i>Scientific Reports</i> , 2018, 8, 16614.	3.3	5
31	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 934-943.	2.4	5
32	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. <i>Biomaterials Science</i> , 2021, 9, 3185-3208.	5.4	5
33	The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants. <i>Atherosclerosis</i> , 2017, 263, e37.	0.8	3
34	Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition. <i>PLoS ONE</i> , 2018, 13, e0204771.	2.5	2
35	Functional characterization of LDL receptor missense variants located in the first cysteine-rich repeat in ligand binding domain of low density lipoprotein receptor. <i>Atherosclerosis</i> , 2017, 263, e102.	0.8	1
36	Ca ²⁺ Influx and Tyr Kinases Trigger Bordetella Cyaa Endocytosis. Cell Physiology and Expression of the CD11B/CD18 Integrin, Major Determinants of the Entry Route. <i>Biophysical Journal</i> , 2014, 106, 89a.	0.5	0

#	ARTICLE	IF	CITATIONS
37	A systematic functional activity characterization of the most frequent GOF and LOF PCSK9 variants. <i>Atherosclerosis</i> , 2018, 275, e153.	0.8	0
38	Functional characterization and classification of frequent variants located in the ldlr beta-propeller. <i>Atherosclerosis</i> , 2018, 275, e166.	0.8	0
39	Kukutxeztula: Â«gainditutakoÂ» gaitz baten itzulera. <i>Ekaia (journal)</i> , 2021, , 61-78.	0.0	0
40	Hiperkolesterolemia Familiarra: patofisiologia, diagnostikoa eta tratamendua. <i>Osagaiz (journal)</i> , 2020, 4, .	0.0	0
41	MLb-LDLr: LDLaren hartzaile aldaeren eragina auresateko ikasketa automatikoko eredu. , 0, , .		0
42	Nanopartikulen lipido konposizioak rHDLen kolesterol kanpora-fluxuaren efizientzia eragina du. , 0, , .		0
43	Familial hypercholesterolemia. , 2022, , 501-524.		0